Genomed

Genomed Financial Leverage

The Financial Leverage (Equity Multiplier) of Genomed (GEN.WA) as of Oct 24, 2026 is 1.17. In the previous year, Financial Leverage (Equity Multiplier) was 1.16 — a change of 1.20% (higher).

Financial Leverage

1.17

YoY

1.20%

Last updated:

Financial Leverage (Equity Multiplier) of Genomed is 2025 1.17 . Financial Leverage (Equity Multiplier) of Genomed was 2024 1.16 . It decreases by 1.20% higher compared to the previous year.

The Genomed Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.23 PLN
Jan 1, 2019
1.24 PLN
Jan 1, 2020
1.32 PLN
Jan 1, 2021
1.17 PLN
Jan 1, 2022
1.14 PLN
Jan 1, 2023
1.20 PLN
Jan 1, 2024
1.16 PLN
Jan 1, 2025
1.17 PLN
The Genomed Financial Leverage history
YEARFinancial LeverageYoY
1.17+1.20%
1.16-3.98%
1.20+6.06%
1.14-3.26%
1.17-11.33%
1.32+6.63%
1.24+0.57%
1.23-12.67%
1.41-13.89%
1.64+6.00%
1.55—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomed Stock analysis

What does Genomed do? Genomed SA generates revenue through molecular diagnostics services based on DNA sequencing, particularly Next Generation Sequencing (NGS). The company offers gene mutation analysis for over 150 congenital diseases including infertility, cancer predisposition, cystic fibrosis, Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy, and obesity. Their primary clients are healthcare providers and research institutions seeking personalized medicine solutions and genomic technology integration. Genomed SA also provides DNA sequencing, analysis, and synthesis services for the biotechnological market, targeting academic and industrial research sectors. The company's business model focuses on developing advanced diagnostic tools for medical applications, with a strong emphasis on NGS technology. Their service portfolio includes specialized genetic testing for congenital conditions and research-oriented DNA services. By concentrating on personalized medicine and gene treatment clinics, Genomed SA positions itself as a provider of specialized genomic solutions for both clinical and research markets. Genomed SA's revenue streams are derived from diagnostic testing services for congenital diseases and biotechnological DNA services. The company serves healthcare facilities requiring genetic analysis for patient care and research organizations needing genomic data for scientific advancement. Their offerings target medical professionals and biotechnology companies seeking to implement genomic technology in their operations. Genomed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomed stock

Financial Leverage (Equity Multiplier) of Genomed is 1.17 in 2025.

Financial Leverage (Equity Multiplier) of Genomed changed from 1.16 to 1.17, representing a 1.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Genomed since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Genomed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Genomed

All Key Metrics — Genomed